Loading
A phase 1 trial of AB-1015 run by Arsenal Biosciences, Inc., terminated.
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer is a phase 1 interventional study registered as NCT05617755 by Arsenal Biosciences, Inc., with 19 participants enrolled, started 2022-11-29. Conditions recorded: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm and Recurrence. Interventions recorded: AB-1015.
Shares Arsenal Biosciences and the tag pipeline.
Shares Arsenal Biosciences and the tag pipeline.
Shares Arsenal Biosciences and the tag pipeline.
Shares Arsenal Biosciences and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/